Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Myovant Sciences Ltd (MYOV)

Myovant Sciences Ltd (MYOV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,367,910
  • Shares Outstanding, K 93,309
  • Annual Sales, $ 59,320 K
  • Annual Income, $ -255,130 K
  • 60-Month Beta 2.79
  • Price/Sales 24.32
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MYOV with:

Options Overview Details

View History
  • Implied Volatility 80.06%
  • Historical Volatility 50.18%
  • IV Percentile 49%
  • IV Rank 17.13%
  • IV High 173.82% on 12/17/20
  • IV Low 60.69% on 08/24/21
  • Put/Call Vol Ratio 0.04
  • Today's Volume 984
  • Volume Avg (30-Day) 538
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 12,550
  • Open Int (30-Day) 9,276

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.56
  • Number of Estimates 4
  • High Estimate -0.50
  • Low Estimate -0.64
  • Prior Year -0.82
  • Growth Rate Est. (year over year) +31.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.29 +2.59%
on 12/03/21
24.08 -39.13%
on 11/04/21
-9.21 (-38.58%)
since 11/03/21
3-Month
14.29 +2.59%
on 12/03/21
27.43 -46.55%
on 09/07/21
-12.09 (-45.20%)
since 09/03/21
52-Week
14.29 +2.59%
on 12/03/21
30.90 -52.56%
on 12/28/20
-9.77 (-39.99%)
since 12/03/20

Most Recent Stories

More News
Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference

BASEL, Switzerland, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for...

MYOV : 14.66 (-5.17%)
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients

Urovant Sciences, Inc., a wholly- owned subsidiary of Sumitovant Biopharma Ltd., announced today that the journal Blood Pressure Monitoring has published the ambulatory blood pressure data on its recently-approved...

MYOV : 14.66 (-5.17%)
Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors

BASEL, Switzerland and LONDON, United Kingdom, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on...

MYOV : 14.66 (-5.17%)
All You Need to Know About Myovant Sciences (MYOV) Rating Upgrade to Buy

Myovant Sciences (MYOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MYOV : 14.66 (-5.17%)
Spirovant to Present SP-101 Data at the 2021 North American Cystic Fibrosis Conference

/PRNewswire/ -- Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF),...

MYOV : 14.66 (-5.17%)
Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates

Myovant Sciences (MYOV) delivered earnings and revenue surprises of 32.35% and 7.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MYOV : 14.66 (-5.17%)
Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates

Second fiscal quarter 2021 total revenues of $77.9 million; net product revenue from U.S. sales of ORGOVYX® of $18.7 million and MYFEMBREE® of $0.6...

MYOV : 14.66 (-5.17%)
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress

BASEL, Switzerland and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the...

MYOV : 14.66 (-5.17%)
Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021

BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for...

MYOV : 14.66 (-5.17%)
Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate

Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today presented data on GEMTESA ® (vibegron) 75 mg in patients with overactive bladder (OAB) at the 2021 Annual Meeting...

MYOV : 14.66 (-5.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral...

See More

Key Turning Points

3rd Resistance Point 16.72
2nd Resistance Point 16.16
1st Resistance Point 15.41
Last Price 14.66
1st Support Level 14.10
2nd Support Level 13.54
3rd Support Level 12.79

See More

52-Week High 30.90
Fibonacci 61.8% 24.55
Fibonacci 50% 22.59
Fibonacci 38.2% 20.63
Last Price 14.66
52-Week Low 14.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar